MV-NIS
AXP000113.1 · Oncolytic virus
- Platform
- measles virus (Edmonston-NSe vaccine lineage)
- Originator
- Mayo Clinic
- Sponsor
- Mayo Clinic
Names
| Name | Type | Source |
|---|---|---|
| MV-NIS | preferred name, code | curator, ncit |
| Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Paramyxoviridae
- Virus
- measles morbillivirus (NCBI Taxonomy 11234)
- Strain
- Edmonston-NSe vaccine lineage
- Replication
- replicating
- Modifications
- NIS cassette inserted for imaging and radioiodine therapy
- Transgenes
- SLC5A5
- Route
- intraperitoneal, intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C66942
Approvals
No regulatory approval recorded.
Clinical trials (11)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03171493 | Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy | Completed | Phase 1 | 2018-07-20 | 2021-02-11 | 8 | Urothelial Carcinoma |
| NCT02919449 | Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab | Terminated | Phase 1 | 2017-08-03 | 2018-01-19 | 2 | Recurrent Non-Small Cell Lung Cancer |
| NCT02700230 | Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery | Completed | Phase 1 | 2017-03-22 | 2024-04-17 | 9 | Metastatic Malignant Peripheral Nerve Sheath Tumor; Neurofibromatosis Type 1; Recurrent Malignant Peripheral Nerve Sheath Tumor |
| NCT02962167 | Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT | Completed | Phase 1 | 2017-02-22 | 2023-05-10 | 34 | Atypical Teratoid/Rhabdoid Tumor; Medulloblastoma Recurrent; Medulloblastoma, Childhood, Recurrent |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | Terminated | Phase 2 | 2015-03-13 | 2022-01-13 | 17 | Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
| NCT02192775 | UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus | Completed | Phase 2 | 2015-03 | 2019-08-20 | 2 | Multiple Myeloma |
| NCT02068794 | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Active not recruiting | Phase 1/2 | 2014-04-25 | 2024-03-15 | 34 | Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Malignant Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
| NCT01846091 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | Completed | Phase 1 | 2013-04-09 | 2019-09-18 | 12 | Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Head and Neck Squamous Cell Carcinoma; Invasive Breast Carcinoma; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Head and Neck Carcinoma; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma |
| NCT01503177 | Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma | Completed | Phase 1 | 2011-11 | 2019-04-11 | 15 | Recurrent Malignant Mesothelioma; Stage IA Malignant Mesothelioma; Stage IB Malignant Mesothelioma; Stage II Malignant Mesothelioma; Stage III Malignant Mesothelioma; Stage IV Malignant Mesothelioma |
| NCT00450814 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma | Completed | Phase 1/2 | 2006-11-30 | 2018-07-10 | 48 | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
| NCT00408590 | Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Completed | Phase 1 | 2004-04-19 | 2012-08 | 37 | Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40540301 | Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in abstract: MV-NIS |
| PMID 33641042 | Systemic Options for Malignant Peripheral Nerve Sheath Tumors. | Current treatment options in oncology | 2021 | cited by trial NCT02700230 |
| PMID 32327728 | Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. | Leukemia | 2020 | name in abstract: MV-NIS |
| PMID 28439108 | Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. | Leukemia | 2017 | name in abstract: MV-NIS |
| PMID 24835528 | Remission of disseminated cancer after systemic oncolytic virotherapy. | Mayo Clinic proceedings | 2014 | name in abstract: MV-NIS |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41741902 | Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. | Journal of neuro-oncology | 2026 | name in abstract: MV-NIS |
| PMID 42625927 | Updated oncolytic viruses for the treatment of bladder cancer: a systematic review. | Iranian journal of microbiology | 2026 | name in abstract: MV-NIS |
| PMID 38941955 | Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. | EBioMedicine | 2024 | name in abstract: MV-NIS |
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: MV-NIS |
| PMID 35487285 | Clinical advances in oncolytic virotherapy for pediatric brain tumors. | Pharmacology & therapeutics | 2022 | name in abstract: MV-NIS |
| PMID 36555262 | Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses. | International journal of molecular sciences | 2022 | name in abstract: MV-NIS |
| PMID 34830842 | The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma. | Cancers | 2021 | name in abstract: MV-NIS |
| PMID 28228086 | Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. | Current cancer drug targets | 2018 | name in abstract: MV-NIS |
| PMID 27604429 | Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice. | Human gene therapy. Clinical development | 2016 | name in abstract: MV-NIS |
| PMID 27782084 | Measles to the Rescue: A Review of Oncolytic Measles Virus. | Viruses | 2016 | name in abstract: MV-NIS |
| PMID 25398436 | Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. | Cancer research | 2015 | name in abstract: MV-NIS |
| PMID 25843626 | Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors. | Gene | 2015 | name in abstract: MV-NIS |
| PMID 25394505 | Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma. | Cancer gene therapy | 2014 | name in abstract: MV-NIS |
| PMID 22914495 | Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. | Gene therapy | 2013 | name in abstract: MV-NIS |
| PMID 23849174 | Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2013 | name in abstract: MV-NIS |
| PMID 21753796 | Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. | Gene therapy | 2012 | name in abstract: MV-NIS |
| PMID 22185260 | Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). | Human gene therapy | 2012 | name in title: MV-NIS |
| PMID 22235810 | Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. | Human gene therapy | 2012 | name in title: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter |
| PMID 22790962 | Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. | Cancer gene therapy | 2012 | name in abstract: MV-NIS |
| PMID 23134812 | Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. | BMC cancer | 2012 | name in abstract: MV-NIS |
| PMID 21703308 | Fluorescein and radiolabeled Function-Spacer-Lipid constructs allow for simple in vitro and in vivo bioimaging of enveloped virions. | Journal of virological methods | 2011 | name in abstract: MV-NIS |
| PMID 20234340 | Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. | Molecular therapy : the journal of the American Society of Gene Therapy | 2010 | name in abstract: MV-NIS |
| PMID 20651188 | Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. | AJR. American journal of roentgenology | 2010 | name in abstract: MV-NIS |
| PMID 19098211 | Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. | AJR. American journal of roentgenology | 2009 | name in abstract: MV-NIS |
| PMID 19169959 | Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. | Current opinion in molecular therapeutics | 2009 | name in abstract: MV-NIS |
| PMID 19773744 | Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. | Molecular therapy : the journal of the American Society of Gene Therapy | 2009 | name in abstract: MV-NIS |
| PMID 17971816 | Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. | Clinical pharmacology and therapeutics | 2007 | name in title: MV-NIS |
| PMID 16328647 | Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. | Molecular imaging and biology | 2006 | name in abstract: MV-NIS |
| PMID 16551872 | Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2006 | name in abstract: MV-NIS |
| PMID 17053863 | In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. | Molecular imaging and biology | 2006 | name in abstract: MV-NIS |
| PMID 14604966 | Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. | Blood | 2004 | name in abstract: MV-NIS |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P50CA116201 | Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancer | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2016–2021 | name in abstract: MV-NIS |
| R01CA200507 | Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2017–2020 | name in abstract: MV-NIS |
| R44CA221461 | INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER | VYRIAD, INC. | RUSSELL, LUKE O. | 2017–2019 | name in abstract: MV-NIS |
| 26120080000 | DCTD Biopharmaceutical Development | LEIDOS BIOMEDICAL RESEARCH, INC. | HEIMBROOK, DAVID | 2008–2018 | name in abstract: MV-NIS |
| R01CA196975 | First in-human PET imaging studies of NIS reporter [18F]BF4 | MAYO CLINIC ROCHESTER | DEGRADO, TIMOTHY R. | 2016–2018 | name in abstract: MV-NIS |
| DP2CA195764 | Oncolytic Virotherapy in Hepatocellular Cancer | MAYO CLINIC ARIZONA | BORAD, MITESH | 2014–2016 | name in abstract: MV-NIS |
| P30CA015083 | Gene and Virus Therapy Program | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2014–2016 | name in abstract: MV-NIS |
| K23CA159391 | Anti-Tumor Immunity in Response to a Modified Vaccine Strain Measles Virus | MAYO CLINIC ROCHESTER | PEIKERT, TOBIAS | 2012–2015 | name in abstract: MV-NIS |
| P50CA108961 | Optimizing Measles Virotherapy in the Treatment of Gliomas | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2004–2015 | name in abstract: MV-NIS |
| R01CA154348 | Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomas | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2011–2014 | name in abstract: MV-NIS |
| R01CA168719 | Measles Virotherapy for Multiple Myeloma | MAYO CLINIC ROCHESTER | RUSSELL, STEPHEN J | 2012–2014 | name in abstract: MV-NIS |
| P50CA136393 | Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2009–2013 | name in abstract: MV-NIS |
| R01CA100634 | Radiovirotherapy for Multiple Myeloma | MAYO CLINIC ROCHESTER | RUSSELL, STEPHEN J | 2003–2012 | name in abstract: MV-NIS |
| R01CA136547 | Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2009–2012 | name in abstract: MV-NIS |
| R01CA125614 | Virotherapy for Relapsed Refractory Multiple Myeloma | MAYO CLINIC ROCHESTER | DISPENZIERI, ANGELA | 2006–2011 | name in abstract: MV-NIS |
| R44CA150283 | Virotherapy for Squamous Cell Carcinoma of the Head and Neck | NISCO INTERNATIONAL, INC. | QIAO, JIAN | 2010–2010 | name in abstract: MV-NIS |
| K08CA103859 | Image-guided Gene and Virotherapy for Pancreatic Cancer | MAYO CLINIC ROCHESTER | CARLSON, STEPHANIE KAY | 2005–2009 | name in abstract: MV-NIS |
| N01CO12400- | DCTD Biopharmaceutical Development | 2007–2007 | name in abstract: MV-NIS |
Notes
Edmonston-lineage measles virus encoding the thyroidal sodium iodide symporter (SLC5A5) for imaging and radiovirotherapy. Separate construct from MV-CEA, tested separately in humans. Also given inside mesenchymal stromal cells in a separate delivery study (carrier, not a separate construct).
How to cite
MV-NIS (AXP000113.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000113.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.